# Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers

> **NCT05353179** · EARLY_PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 88 (estimated)

## Conditions studied

- Granulomatosis With Polyangiitis
- Hemophagocytic Syndrome

## Interventions

- **DRUG:** Meperizumab injection
- **DRUG:** NUCALA®

## Key facts

- **NCT ID:** NCT05353179
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06
- **Primary completion:** 2022-10
- **Final completion:** 2022-10
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05353179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05353179, "Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05353179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*